A Multi-center Phase III Randomized, Double-blind Placebo-controlled Study of the Cancer Vaccine Stimuvax (L-BLP25 or BLP25 Liposome Vaccine) in Non-small Cell Lung Cancer (NSCLC) Subjects With Unresectable Stage III Disease
Phase of Trial: Phase III
Latest Information Update: 06 Dec 2018
At a glance
- Drugs Tecemotide (Primary) ; Cyclophosphamide
- Indications Non-small cell lung cancer
- Focus Registrational; Therapeutic Use
- Acronyms START
- Sponsors EMD Serono; Merck KGaA
- 19 Nov 2015 Status changed from active, no longer recruiting to completed as reported by ClinicalTrials.gov.
- 27 Oct 2014 Planned End Date changed from 1 Oct 2014 to 1 Apr 2015 as reported by ClinicalTrials.gov record.
- 27 Oct 2014 Status changed from completed to active, no longer recruiting as reported by ClinicalTrials.gov record.
Most Recent Events
Table of Contents
- At a glance
- Trial Overview
- Trial Details
- Trial Centres
- Trial History